» Authors » Hind N Alotaibi

Hind N Alotaibi

Explore the profile of Hind N Alotaibi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 17
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Badr A, Alotaibi H, El-Orabi N
Inflammation . 2024 Jul; PMID: 39078585
Doxorubicin (DOX) is an effective chemotherapeutic drug; however, its cardiotoxicity and resistance compromise its therapeutic index. The Notch pathway was reported to contribute to DOX cancer resistance. The role of...
2.
Badr A, Alkharashi L, Sherif I, Alanteet A, Alotaibi H, Mahran Y
Pharmaceuticals (Basel) . 2022 Nov; 15(11). PMID: 36422542
5-Fluorouracil (5-FU) is an anticancer drug with intestinal mucositis (IM) as a deleterious side effect. Thymol is a monoterpene phenol which has been reported to possess an antioxidant and anti-inflammatory...
3.
Alsafwani D, Alotaibi H, Alzaid J, Alghamdi A, Almakhaita H
Cureus . 2022 Apr; 14(4):r57. PMID: 35402110
[This retracts the article DOI: 10.7759/cureus.23554.].
4.
Alsafwani D, Alotaibi H, Alzaid J, Alghamdi A, Almakhaita H
Cureus . 2022 Apr; 14(3):e23554. PMID: 35371841
Background Liraglutide has pleiotropic effects beneficial to patients with cardiovascular and renal risks. These effects have been linked to weight and blood pressure reduction in type 2 diabetes (T2D) patients....
5.
Mahran Y, Badr A, Aldosari A, Bin-Zaid R, Alotaibi H
Oxid Med Cell Longev . 2019 Sep; 2019:3173745. PMID: 31531182
Premature ovarian failure (POF) is a common cause of infertility in premenopausal women who are unavoidably exposed to cytotoxic therapy. Radiotherapy is one of the most effective cytotoxic treatments. However,...